Study of GT719 cell therapy for CD19-positive leukemia or lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study is testing a new cell therapy called GT719 for people with B-cell leukemia or lymphoma that has not responded to standard treatments. The therapy targets a protein called CD19 on cancer cells, aiming to kill them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a B-cell leukemia or lymphoma that has come back or not responded to treatment.
- Your cancer cells have the CD19 protein on their surface.
- Your overall health is good enough to handle daily activities (ECOG score 0 or 1).
- Your kidneys, liver, and heart are working well enough (specific blood tests and heart scan required).
- You are not pregnant, and you agree to use effective birth control for 1 year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called GT719 for adults with B-cell cancers that have come back or not responded to treatment. The cancer cells must have a marker called CD19. The study aims to see if the treatment is safe and works.
This study tests an investigational cell therapy called GT801 for people whose CD19-positive blood cancer (B-ALL, CLL, or B-NHL) or autoimmune hemolytic anemia (AIHA) has not responded to standard treatments. The therapy is made from your own immune cells, modified to target and destroy cancer cells or abnormal immune cells.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
This trial tests a new immune cell therapy (CAR-γδ T cells) that targets a protein called CD19 found on leukemia cells. It is for people with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests if a new cell therapy called GT719 can help people with moderate to severe lupus, inflammatory myopathy, or systemic sclerosis that hasn't gotten better with standard treatments. It aims to find a new option for those who have not responded well to usual medications.
Hear when a new Hematological Malignancy (Leukemia- Lymphoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.